Filing Flows › Regen BioPharma (RGBP) › Q2 FY26
Regen BioPharma (RGBP) Q2 FY26 earnings results (second quarter fiscal 2026)
10-Q filed May 14, 2026
Regen BioPharma (RGBP) reported revenue of $59K for the second quarter fiscal 2026 (Q2 FY26), 0% from a year earlier and 0% from the quarter before. Operating margin was -260.2%.
Regen BioPharma, Q2 FY26: revenue $59K (0% year over year), operating margin -260.2%, net earnings $992K, operating cash flow −$63K. The chart follows the revenue to costs, profit and cash.
| Q2 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $59K | 0% | 0% |
| Operating profit | −$154K | — | — |
| Net earnings | $992K | — | — |
| Operating cash flow | −$63K | — | — |
What changed
Revenue was $59K in Q2 FY26, roughly flat year over year and roughly flat from the previous quarter.
Operating costs exceeded revenue by $154K, an operating margin of -260.2%. Total costs grew 23% against flat revenue. The fastest-growing cost line was General & admin (+141%). Net earnings were $1.0M. The effective tax rate was 0.0%. Non-operating items added $1.1M, 115% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$63K. Working capital and other items used $1.1M.
Questions
What was Regen BioPharma's revenue in the second quarter fiscal 2026?
Regen BioPharma (RGBP) reported revenue of $59K for the second quarter fiscal 2026 (Q2 FY26), 0% from a year earlier and 0% from the quarter before.
Was Regen BioPharma profitable in the second quarter fiscal 2026?
Operating loss was $154K (-260.2% of revenue) and net earnings $992K.
Source: Regen BioPharma 10-Q on SEC EDGAR.